- Home
- OBDC vs NUVL Comparison
OBDC vs NUVL Comparison
Compare OBDC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBDC
- NUVL
- Stock Information
- Founded
- OBDC 2015
- NUVL 2017
- Country
- OBDC United States
- NUVL United States
- Employees
- OBDC N/A
- NUVL N/A
- Industry
- OBDC Investment Managers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OBDC Finance
- NUVL Health Care
- Exchange
- OBDC Nasdaq
- NUVL Nasdaq
- Market Cap
- OBDC 7.7B
- NUVL 5.4B
- IPO Year
- OBDC 2019
- NUVL 2021
- Fundamental
- Price
- OBDC $15.10
- NUVL $85.92
- Analyst Decision
- OBDC Hold
- NUVL Strong Buy
- Analyst Count
- OBDC 8
- NUVL 11
- Target Price
- OBDC $15.64
- NUVL $112.36
- AVG Volume (30 Days)
- OBDC 2.9M
- NUVL 535.6K
- Earning Date
- OBDC 02-19-2025
- NUVL 02-25-2025
- Dividend Yield
- OBDC 6.43%
- NUVL N/A
- EPS Growth
- OBDC N/A
- NUVL N/A
- EPS
- OBDC 1.61
- NUVL N/A
- Revenue
- OBDC $1,613,593,000.00
- NUVL N/A
- Revenue This Year
- OBDC $2.78
- NUVL N/A
- Revenue Next Year
- OBDC $11.69
- NUVL N/A
- P/E Ratio
- OBDC $9.36
- NUVL N/A
- Revenue Growth
- OBDC 6.06
- NUVL N/A
- 52 Week Low
- OBDC $13.98
- NUVL $61.80
- 52 Week High
- OBDC $16.91
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- OBDC 53.46
- NUVL 56.75
- Support Level
- OBDC $14.76
- NUVL $83.71
- Resistance Level
- OBDC $15.15
- NUVL $89.12
- Average True Range (ATR)
- OBDC 0.19
- NUVL 3.27
- MACD
- OBDC 0.04
- NUVL 1.17
- Stochastic Oscillator
- OBDC 79.44
- NUVL 78.60
About OBDC Blue Owl Capital Corporation
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.